Novel Bispecific Antibodies Pumitamig, PF-08634404, and INCA033890-303 Advance to Phase 3 in Colorectal Cancer Trials

Fight Colorectal Cancer USA

Overview

The September 2026 Colorectal Cancer (CRC) clinical trial roundup highlights several promising Phase 3 studies featuring novel bispecific antibodies. These include pumitamig (targeting PD-L1 and VEGF-A), Pfizer’s PF-08634404 (targeting PD-1 and VEGF), and INCA033890-303 (targeting PD-1 and TGFβR2). These agents are being evaluated in combination with standard chemotherapy, including for previously untreated metastatic CRC patients, aiming to improve treatment outcomes by simultaneously engaging multiple oncogenic pathways.

In Depth

Key Findings

The September 2026 Colorectal Cancer (CRC) clinical trial roundup reveals significant progress in the development of next-generation therapies, with several innovative Phase III trials currently underway. A key focus is on novel bispecific antibodies that combine immune checkpoint inhibition with anti-angiogenic or immune-modulatory effects, aiming to improve outcomes for patients with advanced or metastatic CRC when combined with standard chemotherapy. This multi-pronged approach seeks to overcome the limitations of single-target therapies in CRC.

Technical/Clinical Details

Several pivotal Phase III trials are ongoing:

• ROSETTA CRC-203 Study: This trial investigates pumitamig, an investigational bispecific antibody, in combination with standard chemotherapy. Pumitamig targets both PD-L1 (Programmed Death-Ligand 1) and VEGF-A (Vascular Endothelial Growth Factor A). By inhibiting PD-L1, it disarms immune checkpoints to unleash T-cell activity against tumors, while VEGF-A inhibition curtails tumor angiogenesis, thereby disrupting nutrient supply and enhancing anti-tumor effects.
• Pfizer’s PF-08634404 Study: This Phase III trial evaluates Pfizer’s investigational bispecific antibody, PF-08634404, which targets both PD-1 (Programmed Death Receptor 1) and VEGF. The dual blockade is expected to synergistically activate the immune system through PD-1 inhibition and improve the tumor microenvironment for immune cell infiltration through VEGF inhibition.
• INCA033890-303 Study: This Phase III trial explores INCA033890-303, a bispecific antibody targeting PD-1 and TGFβR2 (Transforming Growth Factor beta Receptor 2). TGFβ is a potent immunosuppressive cytokine, and blocking its pathway aims to reverse tumor microenvironment-induced immunosuppression, thereby enhancing the efficacy of PD-1 inhibition. This trial specifically targets previously untreated microsatellite stable (MSS) metastatic CRC patients, a population that has historically shown poor responses to immunotherapies, potentially offering a new therapeutic avenue.

These bispecific antibodies are designed to leverage multiple distinct mechanisms of action, simultaneously targeting various pathways critical for cancer cell proliferation, immune evasion, and angiogenesis, with the expectation of achieving more potent and durable anti-tumor responses.

Background & Context

Colorectal cancer remains one of the leading causes of cancer-related mortality globally, and the prognosis for metastatic CRC, especially the MSS subtype, continues to be challenging. MSS CRC is known for its low response rates to immune checkpoint inhibitors, making the development of novel treatments for this patient population a critical unmet need. Bispecific antibodies, with their ability to target multiple pathways concurrently, represent a cutting-edge class of antibody therapeutics that can achieve therapeutic effects unattainable by single-agent approaches. The success of these Phase III trials could signify a major breakthrough in CRC treatment.

Strategic Significance & Outlook

The outcomes of these Phase III trials are poised to significantly impact CRC treatment guidelines. Should agents like INCA033890-303 prove successful for MSS metastatic CRC patients, they could establish new standards of care for a population that currently lacks effective immunotherapy options. The advancement of these bispecific antibodies underscores a broader trend towards more personalized and multi-faceted cancer treatments, promising to extend survival and enhance the quality of life for CRC patients worldwide. The scientific and clinical communities eagerly await the forthcoming results from these groundbreaking studies.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime